Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GRKs-IN-1 has remarkable potency against and selectivity for G protein-coupled receptor kinase 2 GRK2 (IC50: 130 nM) and GRK5 (IC50: 7.1 μM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 2,420.00 | |
50 mg | 10-14 weeks | $ 3,180.00 | |
100 mg | 10-14 weeks | $ 4,300.00 |
Description | GRKs-IN-1 has remarkable potency against and selectivity for G protein-coupled receptor kinase 2 GRK2 (IC50: 130 nM) and GRK5 (IC50: 7.1 μM). |
Targets&IC50 | GRK2:30 nM, GRK5:7.1 μM |
In vitro | GRKs-IN-1 (Compound 14as) is a derivative 14as of paroxetine, shows a 100-fold improvement in cardiomyocyte contractility assays over paroxetine. |
Synonyms | GRK2-IN-1 |
Molecular Weight | 452.48 |
Formula | C24H25FN4O4 |
CAS No. | 2055990-90-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CCG258208 2055990-90-2 GPCR/G Protein GRK CCG-258208 CCG 258208 GRK2-IN-1 inhibitor inhibit